braf/mek efficacy in braf-mutant nsclc
Published 7 years ago • 204 plays • Length 7:36Download video MP4
Download video MP3
Similar videos
-
4:16
combination therapy in braf-mutant nsclc
-
3:16
nsclc: the braf/mek combination safety profile
-
9:16
changing treatment paradigm for braf-mutant nsclc
-
6:43
considering targeted agents in braf-mutant nsclc
-
2:56
treating braf v600e-mutant nsclc with dabrafenib and trametinib
-
3:10
targeting braf in nsclc
-
2:10
combined treatment with braf and mek inhibitors in metastatic melanomas with braf mutations
-
8:47
braf/mek inhibitors in metastatic melanoma
-
5:55
patient selection in braf-mutant nsclc
-
4:59
outcomes with chemotherapy in braf-mutant nsclc
-
6:27
targeting braf and mek in colorectal cancer
-
3:43
understanding the braf-mutated population in nsclc
-
4:45
gmmg-birma: braf and mek inhibition in mutant braf v600e myeloma
-
6:33
treatment of braf-mutant metastatic melanoma
-
3:53
targeted therapies for braf v600e-mutated mnsclc
-
6:05
duration of dual braf-mek inhibition
-
4:01
alk inhibitors and braf/mek inhibitors for nsclc
-
3:49
dual targeting of brak and mek in nsclc
-
3:51
combining braf, mek and egfr inhibition in mcrc